| Prosthesis prototype eyed for testing in volunteers
| | Ophthalmology Times | A collaborative effort to design an intracortical visual prosthesis has progressed to the point that tests of a prototype in a human volunteer are being planned. The results of psychophysical testing in normal volunteers indicate that the prosthesis could provide sufficient visual functionality to enable users to perform useful visual tasks. |
| | Electromagnetic deformable mirror assists in retinal diagnostics
| Device reduces impact of ocular aberrations on imaging for clearer results
| | Ophthalmology Times | |
The novel technology found at the heart of an adaptive optics flood illumination fundus camera (AOFIFC, INOVEO)—an electromagnetic deformable mirror (Mirao 52-e, Imagine Eyes)—is designed to facilitate the acquisition of even higher resolution images than those captured by optical coherence tomography systems. |
| | Choroidal neovascularization future treatment may be combination therapy
| Adjuvant use also results in better visual acuity outcomes, study shows
| | Ophthalmology Times | | Adjuvant use of bromfenac ophthalmic solution 0.09% (Xibrom, ISTA Pharmaceuticals) with ranibizumab (Lucentis, Genentech) reduced the reduced the number of ranibizumab injections needed to control choroidal neovascularization secondary to age-related macular degeneration. Use of the two drugs together resulted in better visual acuity outcomes than those achieved with ranibizumab alone. |
| | Diabetic macular edema intravitreal insert treatment aims high
| Preliminary results show that device holds promise for release of corticosteroid at varying doses
| | Ophthalmology Times | | A new intravitreal insert (Iluvien, Alimera Sciences) currently in clinical trials manages a slow, long-term release of corticosteroid into the vitreous chamber. Preliminary results show the device to be very promising and possibly more favorable than other similar devices used for the treatment of diabetic macular edema. |
| | Age-related macular degeneration and diabetic retinopathy phase III trials show promise
| Diseases are two most important public health problems in ophthalmology in developed world
| | Ophthalmology Times | | Drug development for retinal disease is particularly challenging because traditional routes of drug delivery often are unable to achieve desired therapeutic levels, and the disease process often involves multiple complex pathways. An unmet medical need still exists—particularly for the two most prevalent diseases, age-related macular degeneration and diabetic retinopathy—but several phase III trials show promise. |
|
| Wet AMD 18-month data unveiled
| | Ophthalmology Times | | The 18-month data of a proprietary epiretinal brachytherapy (NeoVista) for the treatment of wet age-related macular degeneration were made public at the recent Retina Society annual meeting. |
| | Antioxidants key to prevent blindness
| | Ophthalmology Times | | It has just been discovered by researchers at Brigham Young University and Weill Medical College of Cornell University that two processes in the retina, which in combination contribute to age-related macular degeneration, can be disrupted by antioxidants. |
| | | UV rays don't just damage skin
| | Ophthalmology Times | | Prevent Blindness has dedicated May as UV Awareness Month in an effort to educate the public on the best way to protect their eyes. |
| | Risk of glaucoma increases with diabetes, study supports
| | Ophthalmology Times | | It appears that diabetic retinopathy is not the only eye disease associated with diabetes, according to a study, which found that women with diabetes have about a 70% increased risk of developing the most common form of glaucoma—primary-open angle glaucoma—compared with women without diabetes. |
|
| 
